Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Long-term outcome for prostate cancer using pseudo pulse-dosed rate brachytherapy, external beam radiotherapy, and hormones.

Izard MA, Morris LM, Wan WY, Martin J.

Brachytherapy. 2013 Nov-Dec;12(6):608-14. doi: 10.1016/j.brachy.2013.04.004. Epub 2013 May 7.

PMID:
23664646
2.

Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?

Morris LM, Izard MA, Wan WY.

Brachytherapy. 2015 May-Jun;14(3):322-8. doi: 10.1016/j.brachy.2014.11.002. Epub 2014 Dec 5.

PMID:
25487524
3.

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.

Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31.

PMID:
16029788
4.

Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.

Lettmaier S, Lotter M, Kreppner S, Strnad A, Fietkau R, Strnad V.

Radiother Oncol. 2012 Aug;104(2):181-6. doi: 10.1016/j.radonc.2012.07.003. Epub 2012 Jul 30.

PMID:
22853851
5.

Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer.

Kotecha R, Yamada Y, Pei X, Kollmeier MA, Cox B, Cohen GN, Zaider M, Zelefsky MJ.

Brachytherapy. 2013 Jan-Feb;12(1):44-9. doi: 10.1016/j.brachy.2012.05.003. Epub 2012 Jul 24.

6.

Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.

Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, Eulau S, Gustafson G, Gribble M, Kovács G.

Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048-55.

PMID:
15001244
7.

Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.

Valero J, Cambeiro M, Galán C, Teijeira M, Romero P, Zudaire J, Moreno M, Ciérvide R, Aristu JJ, Martínez-Monge R.

Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):386-92. doi: 10.1016/j.ijrobp.2009.01.059. Epub 2009 May 8.

PMID:
19427741
8.
9.

Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.

Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, Edmundson GK, Spencer W, Vicini FA.

Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):343-52.

PMID:
10802358
10.
11.

A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.

Vargas C, Ghilezan M, Hollander M, Gustafson G, Korman H, Gonzalez J, Martinez A.

J Urol. 2005 Sep;174(3):882-7.

PMID:
16093980
12.

High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer.

Zwahlen DR, Andrianopoulos N, Matheson B, Duchesne GM, Millar JL.

Brachytherapy. 2010 Jan-Mar;9(1):27-35. doi: 10.1016/j.brachy.2009.04.007. Epub 2009 Oct 20.

PMID:
19846348
13.

Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer.

Izard MA, Haddad RL, Fogarty GB, Rinks A, Dobbins T, Katelaris P.

Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):38-47.

PMID:
16904516
14.

High-dose-rate brachytherapy of a single implant with two fractions combined with external beam radiotherapy for hormone-naive prostate cancer.

Sato M, Mori T, Shirai S, Kishi K, Inagaki T, Hara I.

Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1002-9. doi: 10.1016/j.ijrobp.2008.02.055. Epub 2008 Apr 28.

PMID:
18448272
15.

High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up.

Ishiyama H, Satoh T, Kitano M, Tabata K, Komori S, Ikeda M, Soda I, Kurosaka S, Sekiguchi A, Kimura M, Kawakami S, Iwamura M, Hayakawa K.

J Radiat Res. 2014 May;55(3):509-17. doi: 10.1093/jrr/rrt128. Epub 2013 Nov 11.

16.

Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer.

Koontz BF, Chino J, Lee WR, Hahn CA, Buckley N, Huang S, Kim J, Reagan R, Joyner R, Anscher MS.

Brachytherapy. 2009 Apr-Jun;8(2):191-6. doi: 10.1016/j.brachy.2009.01.002.

PMID:
19433320
17.

Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer.

Martinez AA, Gustafson G, Gonzalez J, Armour E, Mitchell C, Edmundson G, Spencer W, Stromberg J, Huang R, Vicini F.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):316-27.

PMID:
12023135
18.

3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer.

Martin T, Röddiger S, Kurek R, Dannenberg T, Eckart O, Kolotas C, Heyd R, Rogge B, Baltas D, Tunn U, Zamboglou N.

Radiother Oncol. 2004 Apr;71(1):35-41.

PMID:
15066294
19.

Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer.

Lilleby W, Tafjord G, Raabe NK.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):933-9. doi: 10.1016/j.ijrobp.2011.08.028. Epub 2011 Dec 2.

PMID:
22138456
20.

Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer.

Khor R, Duchesne G, Tai KH, Foroudi F, Chander S, Van Dyk S, Garth M, Williams S.

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):679-85. doi: 10.1016/j.ijrobp.2012.07.006. Epub 2012 Sep 3.

PMID:
22954770

Supplemental Content

Support Center